Rapport Therapeutics, Inc. (NASDAQ:RAPP) disclosed that Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares of the company's common stock on April 8, 2026, at $34.90 per share, producing proceeds of $12,564. Following the transaction, Krishnaswamy directly holds 286,516 shares.
The sale was carried out pursuant to a pre-established Rule 10b5-1 trading plan that was adopted on December 10, 2025. At the time of reporting, Rapport Therapeutics stock is trading at $34.22, representing a 275% increase over the past year.
Separately, the company has taken steps to advance its lead candidate RAP-219. Rapport Therapeutics said it will present data from the Phase 2a trial of RAP-219 at the 2026 American Academy of Neurology Annual Meeting. The presentation follows the company's fiscal year 2025 earnings release, which included Phase IIa clinical data for RAP-219 in focal seizures.
Management also announced an acceleration of its development timetable: the pivotal Phase 3 program in focal onset seizures is now planned to start earlier than previously expected, with trials scheduled to begin in the second quarter of 2026.
Brokerage coverage following these program updates and the fiscal 2025 results shows continuing optimism among several firms. Truist Securities reiterated a Buy rating with a $44.00 price target. Stifel maintained its Buy rating and kept a $56.00 price target, calling out the accelerated timing of the Phase 3 program. BTIG increased its price target to $53 from $47 while maintaining a Buy rating, citing progress in trial developments and potential expansion opportunities. Jones Trading also reiterated a Buy rating with a $50.00 price target after the fiscal 2025 earnings disclosure.
These analyst actions and the company’s disclosure of clinical timelines reinforce Rapport Therapeutics’ current operational focus on advancing RAP-219 and evaluating related therapeutic opportunities.
Summary
A company executive sold a small number of shares under a pre-arranged trading plan while the business moves RAP-219 toward a pivotal Phase 3 trial and prepares to present Phase 2a data. Multiple brokerages have reaffirmed or raised price targets following the company’s recent updates.